Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLPP | Q16740 | 5/20 | 0.62 |
| ▸ | MMP13 | P45452 | 9/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6494214 | 0.94 | CLPP (0.59) | CLPPMMP13CYP1A2GAACYP2C9 | |
| SCHEMBL6486140 | 0.91 | CLPP (0.52) | CLPPMMP13CYP1A2GAACYP2C9 | |
| SCHEMBL6485895 | 0.91 | CLPP (0.52) | CLPPMMP13CYP1A2GAACYP2C9 | |
| SCHEMBL6491039 | 0.91 | CLPP (0.52) | CLPPMMP13CYP1A2GAACYP2C9 | |
| SCHEMBL6500875 | 0.90 | CLPP (0.53) | CLPPMMP13CYP1A2GAACYP2C9 | |
| SCHEMBL6497773 | 0.89 | CLPP (0.50) | CLPPMMP13CYP1A2GAACYP2C9 | |
| SCHEMBL6487777 | 0.89 | CLPP (0.50) | CLPPMMP13 | |
| SCHEMBL6486742 | 0.89 | CLPP (0.50) | CLPPMMP13CYP1A2GAACYP2C9 | |
| SCHEMBL6487633 | 0.89 | CLPP (0.63) | CLPPMMP13 | |
| SCHEMBL6488378 | 0.88 | CLPP (0.53) | CLPPMMP13CYP1A2GAACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6869958-B2 | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-03-22 | — | — | US | disclosed |
| US-20040038960-A1 | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors | LI JIE JACK (US) | 2004-02-26 | — | — | US | disclosed |
| WO-2004014909-A1 | FUSED TETRAHYDROPYRIDINE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038960-A1 | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors | MMP9, MMP3, MMP13 | CLPP 3602/4885MMP13 3/4885CYP1A2 787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.